SAN DIEGO--(BUSINESS WIRE)--BeneChill, Inc. (“BeneChill”, the “Company”) announced positive results from the COOLHEAD Clinical Study. The purpose of the study was to determine the effectiveness of intranasal evaporative cooling for the treatment of acute migraine headaches.
The open-label, observational study consisted of 15 adult patients (M=3, F=12) with an average age of 43 years. All patients satisfied the International Classification of Headache Disorders (ICHD 2) criteria for either episodic (with or without aura), or chronic migraine. Patients in this trial were categorized as having severe migraine with 93% recording a normal historical duration of pain and symptoms of more than 24 hours, when using standard treatments, while 46% of the patients had typical migraines lasting up to 72 hours. The historical baseline of migraine Pain Severity (VAS 0-10 with 0 = no pain/discomfort and 10 = severe pain/discomfort) for this patient group averaged a score of 8, with modes of 9 and 10. All patients stated that they had multiple migraine attacks per month.
Help employers find you! Check out all the jobs and post your resume.
The open-label, observational study consisted of 15 adult patients (M=3, F=12) with an average age of 43 years. All patients satisfied the International Classification of Headache Disorders (ICHD 2) criteria for either episodic (with or without aura), or chronic migraine. Patients in this trial were categorized as having severe migraine with 93% recording a normal historical duration of pain and symptoms of more than 24 hours, when using standard treatments, while 46% of the patients had typical migraines lasting up to 72 hours. The historical baseline of migraine Pain Severity (VAS 0-10 with 0 = no pain/discomfort and 10 = severe pain/discomfort) for this patient group averaged a score of 8, with modes of 9 and 10. All patients stated that they had multiple migraine attacks per month.
Help employers find you! Check out all the jobs and post your resume.
